Cargando…

Biological Drug Products : Development and Strategies.

Tested and proven solutions to the challenges of biological drug product development Biological drug products play a central role in combating human diseases; however, developing new successful biological drugs presents many challenges, including labor intensive production processes, tighter regulat...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Wang, Wei
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Wiley, 2013.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000Ma 4500
001 EBOOKCENTRAL_ocn858654001
003 OCoLC
005 20240329122006.0
006 m o d
007 cr |n|||||||||
008 130920s2013 xx ob 001 0 eng d
040 |a IDEBK  |b eng  |e pn  |c IDEBK  |d OCLCQ  |d E7B  |d EBLCP  |d CCO  |d OCLCO  |d COO  |d OCLCF  |d OCLCQ  |d LOA  |d COCUF  |d MOR  |d PIFPO  |d ZCU  |d MERUC  |d OCLCQ  |d U3W  |d STF  |d OCLCQ  |d NRAMU  |d ICG  |d OCLCQ  |d TKN  |d DKC  |d OCLCQ  |d HS0  |d OCLCQ  |d VLY  |d TUHNV  |d OCLCO  |d OCLCA  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCL 
019 |a 961554441 
020 |a 1299864651  |q (ebk) 
020 |a 9781299864658  |q (ebk) 
020 |a 9781118695036  |q (ebk.) 
020 |a 1118695038  |q (ebk.) 
020 |a 9781118148891 
020 |a 1118148894 
029 1 |a AU@  |b 000053337265 
029 1 |a DEBBG  |b BV044063039 
029 1 |a NZ1  |b 15493662 
035 |a (OCoLC)858654001  |z (OCoLC)961554441 
037 |a 517716  |b MIL 
050 4 |a QV241 
060 1 0 |a QV 241 
082 0 4 |a 615.1  |a 615.1/9 
049 |a UAMI 
100 1 |a Wang, Wei. 
245 1 0 |a Biological Drug Products :  |b Development and Strategies. 
260 |b Wiley,  |c 2013. 
300 |a 1 online resource 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
588 0 |a Print version record. 
504 |a Includes bibliographical references and index. 
505 0 |a Biological Drug Products: Development and Strategies; Contents; Preface; Contributors; Part 1: General Aspects; 1 An Overview of the Discovery and Development Process for Biologics; 1.1 INTRODUCTION; 1.2 THE DISCOVERY PROCESS FOR MONOCLONAL ANTIBODIES; 1.2.1 Target Selection; 1.2.2 Screening Preparation; 1.2.3 Lead Selection and Optimization; 1.2.4 Selection of a Clinical Candidate; 1.2.5 Key Differences in the Discovery Process for Monoclonal Antibodies Versus Small Molecule Drugs; 1.3 MANUFACTURING PROCESS DEVELOPMENT FOR BIOLOGICS; 1.3.1 Introduction 
505 8 |a 1.3.2 Early Assessment of Discovery Candidate(s)1.3.3 Bioprocess Development and Manufacture; 1.3.4 Formulation Process Development and Manufacture; 1.3.5 Analytical Method Development and Manufacture; 1.3.6 Project Management and Critical Path to the Clinic; 1.4 REGULATORY REVIEWAND APPROVAL FOR BIOLOGICS; 1.4.1 US Drug Law; 1.4.2 Food and Drug Administration Overview; 1.4.3 Drug Development in the United States; 1.4.4 US Generic and Biosimilar Legislation; 1.5 BIOLOGICS: THE PAST, THE PRESENT, AND THE FUTURE; 1.5.1 Biosimilars; 1.5.2 Novel Scaffolds; 1.5.3 Drug Delivery 
505 8 |a 1.5.4 Immunogenicity1.5.5 Streamline the Drug Discovery and Development Process; 1.6 CONCLUSION; REFERENCES; 2 Nonclinical Safety Assessment of Biologics, Including Vaccines; 2.1 INTRODUCTION; 2.2 CONSIDERATIONS IN THE SELECTION OF THE ANIMAL SPECIES; 2.2.1 General Introduction; 2.2.2 Sequence Homology; 2.2.3 Target Affinity, Distribution, Biology, and Biochemical Pathways; 2.2.4 Use of Genetically Altered Rodents and Surrogate Antibodies; 2.2.5 Use of Animal Models of Disease; 2.3 CONSIDERATIONS FOR THE NONCLINICAL SAFETY EVALUATION; 2.3.1 Route of Administration 
505 8 |a 2.3.2 Selection of Doses for Toxicity Studies2.3.3 Safety Pharmacology; 2.3.4 General Toxicology Studies; 2.4 PHARMACOKINETICS; 2.4.1 Absorption; 2.4.2 Distribution; 2.4.3 Metabolism; 2.4.4 Excretion; 2.5 SELECTION OF THE INITIAL CLINICAL DOSE; 2.6 FUTURE DIRECTIONS; REFERENCES; 3 Clinical Assessment of Biologic Agents; 3.1 INTRODUCTION; 3.2 CLINICALTRIAL STRUCTURE; 3.2.1 Study Objective and Hypothesis Testing; 3.2.2 Standard Phases of Clinical Trials; 3.2.3 Types of Studies; 3.3 INCORPORATING PATIENTS INTO THE STRUCTURE OFATRIAL; 3.3.1 Treatment Groups and Cohort Enrichment 
505 8 |a 3.3.2 Comparative GroupsWithin Clinical Trials3.4 EFFICACY; 3.4.1 Endpoints; 3.5 PHARMACOVIGILANCE; 3.5.1 Adverse Side Effects; 3.6 DISEASES TREATED WITH BIOLOGICS; 3.6.1 Rheumatoid Arthritis; 3.6.2 Osteoporosis and Malignant Bone Metastasis; 3.6.3 Inflammatory Bowel Disease; 3.6.4 Psoriasis and Psoriatic Arthritis; 3.6.5 Reactive Airway Disease; 3.7 FUTURE PERSPECTIVES; REFERENCES; 4 Key Regulatory Guidelines for the Development of Biologics in the United States and Europe; 4.1 INTRODUCTION; 4.2 GENERAL UNITED STATES REGULATORY SCHEME 
520 |a Tested and proven solutions to the challenges of biological drug product development Biological drug products play a central role in combating human diseases; however, developing new successful biological drugs presents many challenges, including labor intensive production processes, tighter regulatory controls, and increased market competition. This book reviews the current state of the science, offering readers a single resource that sets forth the fundamentals as well as tested and proven development strategies for biological drugs. Moreover, the book prepares readers for th. 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
650 0 |a Drug development. 
650 0 |a Drugs  |x Research. 
650 1 2 |a Biological Products  |x pharmacology 
650 2 2 |a Biological Products  |x therapeutic use 
650 2 2 |a Drug Delivery Systems 
650 2 2 |a Drug Discovery 
650 6 |a Médicaments  |x Développement. 
650 6 |a Médicaments  |x Recherche. 
650 7 |a Drug development  |2 fast 
650 7 |a Drugs  |x Research  |2 fast 
758 |i has work:  |a Biological drug products (Text)  |1 https://id.oclc.org/worldcat/entity/E39PCGDGBkjJpPWYCYD4bTRwJC  |4 https://id.oclc.org/worldcat/ontology/hasWork 
776 0 8 |i Print version:  |z 9781299864658 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=1368915  |z Texto completo 
938 |a EBL - Ebook Library  |b EBLB  |n EBL1368915 
938 |a ebrary  |b EBRY  |n ebr10763013 
938 |a ProQuest MyiLibrary Digital eBook Collection  |b IDEB  |n cis26193832 
994 |a 92  |b IZTAP